Tuesday, June 07, 2022 10:55:01 AM
Recent VAXX News
- Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 • GlobeNewswire Inc. • 03/07/2024 03:32:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:15:34 PM
- Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published • GlobeNewswire Inc. • 02/15/2024 01:00:14 PM
- Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 • GlobeNewswire Inc. • 02/13/2024 01:00:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:02:04 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:02:01 PM
- Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida • GlobeNewswire Inc. • 01/30/2024 01:00:56 PM
- Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida • GlobeNewswire Inc. • 01/18/2024 01:00:58 PM
- Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 01:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 03:30:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/30/2023 10:03:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/30/2023 09:54:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/29/2023 10:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/29/2023 10:10:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/21/2023 09:21:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/21/2023 09:20:06 PM
- Vaxxinity to Present at Upcoming November Medical and Investor Conferences • GlobeNewswire Inc. • 11/13/2023 11:50:00 PM
- Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/08/2023 01:30:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:53:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:31:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/04/2023 08:33:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/04/2023 08:24:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:15:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/22/2023 08:16:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/22/2023 08:12:08 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM